Introduction {#s1}
============

Microbial genome sequencing and bacterial genome-wide association studies (GWAS) present new opportunities to discover bacterial genes involved in the pathogenesis of serious infections ([@bib47]; [@bib7]; [@bib17]; [@bib28]; [@bib18]; [@bib42]). Pyomyositis is a severe infection of skeletal muscle most commonly seen in children in the tropics ([@bib6]; [@bib54]; [@bib2]). In up to 90% of cases, it is caused by a single bacterial pathogen, *Staphylococcus aureus* (*S. aureus*) ([@bib6]; [@bib54]; [@bib2]; [@bib36]). Unlike infections of the skin and superficial soft tissues, the skin and subcutaneous tissues are not usually involved in pyomyositis, by contrast to intense inflammation in the infected muscles ([@bib6]; [@bib54]). Pyomyositis is thought to arise from haematogenous seeding of bacteria from blood to muscle ([@bib54]). There is evidence that some *S. aureus* strains have heightened propensity to cause pyomyositis -- the incidence in the USA doubled during an epidemic of community-associated methicillin resistant *S. aureus* (CA-MRSA) ([@bib41]) -- but molecular genetic investigation of *S. aureus* from pyomyositis has been limited ([@bib5]).

Panton--Valentine leucocidin (PVL), a well-known staphylococcal toxin causing purulent skin infections and found in epidemics caused by CA-MRSA, has been implicated in pyomyositis, pneumonia and other *S. aureus* disease manifestations, but its role in these invasive infections is disputed ([@bib46]; [@bib53]; [@bib25]; [@bib55]). PVL is a bipartite pore-forming toxin comprising the co-expressed LukF-PV and LukS-PV proteins ([@bib31]; [@bib3]). The coding sequence for PVL, *lukSF-PV*, is usually carried on bacteriophages, ([@bib46]; [@bib31]), which facilitate *lukSF-PV* exchange between lineages ([@bib33]). The mechanism of PVL toxicity has been shown to involve cell lysis in human myeloid cells, particularly neutrophils, by insertion into the cellular membrane, ([@bib38]) leading the tissue to release inflammatory neutrophil products ([@bib49]). Neutrophil lysis is mediated by PVL binding to target complement receptors C5aR; in binding, PVL has both toxic and immunomodulatory effects, as it also inhibits C5a mediated immune activation ([@bib48]).

Although small case series testing for candidate genes have reported a high prevalence of PVL among pyomyositis-causing *S. aureus*, ([@bib41]; [@bib48]; [@bib20]) a detailed meta-analysis found no evidence for an increased rate of musculoskeletal infection (or other invasive disease) in PVL-positive bacteria versus controls ([@bib46]). These conflicting results may reflect insufficiently powered studies, and some case series lack comparative control strains ([@bib48]). A further problem with the use of candidate gene studies in studying pathogenesis is that they may miss important variation elsewhere in the genome. One study reporting a critical role for PVL in the causation of severe pneumonia ([@bib25]) was later found to have overlooked mutations in key regulatory genes, capable of producing the virulence that had been attributed to PVL by the original study ([@bib55]). Thus, while some evidence suggests an association between pyomyositis and PVL, there remains significant uncertainty regarding the bacterial genetic predisposition of *S. aureus* to pyomyositis, and whether PVL is an important virulence factor, or merely an epiphenomenon, carried by bacteria alongside unidentified genetic determinants ([@bib40]; [@bib11]).

GWAS offer a means to screen entire bacterial genomes to discover genes and genetic variants associated with disease risk. They are particularly appealing because they enable the investigation of traits not readily studied in the laboratory, and do not require the nomination of specific candidate genes ([@bib18]). Proof-of-principle GWAS in bacteria have demonstrated the successful rediscovery of known antimicrobial resistance (AMR) determinants ([@bib7]; [@bib17]; [@bib28]). However, AMR is under extraordinarily intense selection in bacteria. More subtle traits, including host specificity ([@bib47]) and the duration of pneumococcal carriage, ([@bib29]) have also been demonstrated using GWAS. Promising results for GWAS in human infecting bacteria include identifying possible loci for invasive infection with *Streptococcus pyogenes* ([@bib28]) and *Staphylococcus epidermidis* ([@bib34]),and the identification of virulence-associated genes corresponding with regional differences in disease manifestations of melioidosis ([@bib8]). Within species, lineage-specific variants have been shown to predict mortality following *S. aureus* bacteraemia ([@bib43]). These studies support the potential GWAS has to precisely pinpoint genes and genetic variants underlying the propensity to cause specific human infections, making it a promising tool to investigate the possible contribution of bacterial genomic variation to pyomyositis.

Results {#s2}
=======

To understand the bacterial genetic basis of pyomyositis, we sampled and whole-genome sequenced *S. aureus* from 101 pyomyositis infections and 417 asymptomatic nasal carriage episodes in 518 children attending Angkor Hospital for Children in Siem Reap, Cambodia between 2008 and 2012 ([Supplementary file 1](#supp1){ref-type="supplementary-material"}). As expected, we observed representatives of multiple globally common lineages in Cambodia, together with some globally less common lineages at high frequency, in particular clonal complex (CC) 121, identified by multi-locus sequence typing (MLST). There were no major changes in lineage frequency over time ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}).

In our study, some *S. aureus* lineages were strongly overrepresented among cases of pyomyositis compared with asymptomatic, nasally-carried controls over the same time period. Notably, 86/101 (85%) of pyomyositis cases were caused by CC-121 bacteria, whereas no pyomyositis cases were caused by the next two most commonly carried lineages, sequence type (ST)−834 and CC-45 ([Figure 1](#fig1){ref-type="fig"}). We estimated the overall heritability of case/control status to be 63.8% (95% CI 49.2--78.4%) in the sample, reflecting the strong relationship between bacterial genetic variation and case/control status. We used *bugwas* ([@bib42]) to decompose this heritability into the principal components (PCs) of bacterial genetic variation. PC 1, which distinguished CC-121 (the most common pyomyositis lineage) from ST-834 (which was only found in carriage), showed the strongest association with case/control status (p=10^-29.6^, Wald test). The strongest association was with PC 20, which differentiated a sub-lineage of CC-121 within which no cases were seen (p=10^-13.9^), and PC 2, which distinguished CC-45 from the rest of the species (p=10^-4.9^).

![Phylogeny of *S. aureus* cultured from children in Cambodia shows strong strain-to-strain variation in pyomyositis prevalence.\
The phylogeny was estimated by maximum likelihood from SNPs mapping to the USA300 FPR3757 reference genome. Multi-locus sequence type (ST) or clonal complex (CC) groups are shown (outer grey ring). Case/control status is marked in the middle ring: pyomyositis (gold, n = 101) or nasal carriage (green, n = 417). Branches of the phylogeny that correspond to the three principal components (PCs) significantly associated with case/control status (PCs 1, 2 and 20) are marked in red, blue and yellow, respectively. Branch lengths are square root transformed to aid visualization. The presence of the kmers most strongly associated with pyomyositis is indicated by red blocks in the inner ring.](elife-42486-fig1){#fig1}

We conducted a GWAS to identify bacterial genetic variants associated with pyomyositis, controlling for differences in pyomyositis prevalence between *S. aureus* lineages. We used a kmer-based approach ([@bib47]) in which every variably present 31 bp DNA sequence observed among the 518 genomes was tested for association with pyomyositis *versus* asymptomatic nasal carriage, controlling for population structure using GEMMA ([@bib60]). These kmers captured bacterial genetic variation including single nucleotide polymorphisms (SNPs), insertions or deletions (indels), and presence or absence of entire accessory genes. We found 10.7 million unique kmers variably present across the bacterial genomes. In total, 9175 kmers were significantly associated with case/control status after correction for multiple testing (10^-6.8^ ≤ *p* ≤ 10^-21.4^; [Figure 2A](#fig2){ref-type="fig"}). When mapped to the de novo assembly of a CC121 isolate from pyomyositis (PYO2134), the vast majority of these kmers (9,074/9,175; 98.9%) localised to a 45.7 kb region spanning an integrated prophage with 95% nucleotide identity to φSLT ([Figure 2B](#fig2){ref-type="fig"}). Most (9,173/9,175; 99.98%) significant kmers were found at an increased frequently in pyomyositis, with odds ratios (OR) ranging from 2.7 to 139.8, indicating that the presence of each was associated with increased risk of disease. The presence of bacteriophage φSLT was thus strongly associated with pyomyositis.

![Kmers associated with pyomyositis.\
(**A**) All kmers (n = 10,744,013) were mapped to the genome assembly of one CC121 pyomyositis bacterium (PYO2134). Each point represents a kmer, plotted by the mapped location and the significance of the association with disease (-log~10~ *p* value). Kmers are coloured by the odds ratio (OR) of kmer presence for disease risk. A Bonferroni-adjusted threshold for significance is plotted in grey. (**B**) The region between 1.57--1.62 MB in greater detail. Grey arrows depict coding sequences, determined by homology to USA300 FPR3757. (**C**) Associations for kmers mapping to region 1,571--1574 kB is plotted. Kmer presence determined from hybrid assembly using short and long-read data. Grey arrows depict coding sequences, determined by homology to USA300 FPR3757.](elife-42486-fig2){#fig2}

We were able to localise the most statistically significant signal of association to kmers that mapped within φSLT to the *lukS-PV* and *lukF-PV* cargo genes. These genes encode the subunits of PVL, which multimerise into a pore-forming toxin capable of rapidly lysing the membranes of human neutrophils ([@bib31]; [@bib40]). 1630 kmers tagging the presence of the *lukSF-PV* coding sequences (CDS) were highly significantly associated with disease, being present in 98/101 (97%) pyomyositis cases and 84/417 (20%) carriage controls (unadjusted OR 129.5, p=10^-17.9^). Kmers tagging variation in the 389 bp region immediately upstream of the CDS were also strongly associated with disease (p=10^-21.4^). The most significant of these kmers were co-present with the CDS in the same cases (98/101, 97.0%), but present in fewer controls (79/417, 18.9%), producing an OR of 140.

Closer examination of this \~400 bp upstream region in genomes assembled from short-read Illumina sequencing showed that assembly of the region was problematic, with breaks or gaps in the assembly ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). To improve the accuracy of this region of the assembled genomes we performed long-read Oxford Nanopore sequencing on the 37 genomes with incomplete or discontinuous assembly upstream of the PVL CDS. By integrating long-read and short-read data we were able to assemble a single contig spanning this region in all isolates ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). When these improved assemblies were introduced, the signal of association upstream of the PVL CDS was no more significant than within the CDS ([Figure 2C](#fig2){ref-type="fig"}). Therefore, the presence of genomic sequence spanning the PVL toxin-coding sequences and the upstream, presumed regulatory, region exhibited the strongest association with pyomyositis in the *S. aureus* genome. All isolates with kmers mapping to the PVL CDS had 98% or more coverage for the PVL CDS genes in de novo assembly ([Figure 2---figure supplement 3](#fig2s3){ref-type="fig"}). The signal of association in the earlier and later periods of the study were examined and found to be consistent ([Figure 2---figure supplement 4](#fig2s4){ref-type="fig"}).

Out of 9175 kmers significantly associated with pyomyositis, we only found 101 kmers related to regions outside the PVL-carrying prophage ([Figure 2A](#fig2){ref-type="fig"}, [Supplementary file 2](#supp2){ref-type="supplementary-material"}). Two kmers mapping at a position near 0.2 Mb in the PYO2014 reference genome showed homology to platelet adhesin *sraP* by BLAST. Thirty-five kmers mapping to a 50 bp non-coding fragment at 0.6 Mb and two kmers mapping to 2.8 Mb showed homology to an MSSA476 intergenic sequence between adhesin-encoding *sdrC* and *sdrD* by BLAST. One kmer mapping to position 2.0 Mb showed no sequence homology by BLAST. Sixty-one kmers mapping to a 61 bp non-coding region at 2.7 Mb showed homology to an MSSA476 intergenic sequence between acetyltransferase-encoding genes SAS2453 and SAS2454 by BLAST. In conclusion, these other signals were short, fragmentary and mostly non-coding so we did not investigate them further.

The presence of high-risk kmers mapping to the PVL region explained the vast majority of observed heritability. When the presence or absence of the most significant kmer pattern, a set of kmers with an identical pattern of presence in the population, all of which mapped to the PVL region, was included as a covariate in GEMMA, the remaining heritability not explained by other factors was estimated and found to be 0.0% (95% CI 0--2.5%). Thus, the point estimate for heritability (not explained by the inclusion of PVL-tagging kmers) is reduced by 100% (95% CI 93.5--100%), meaning we have little evidence for any remaining heritability in case/control status.

Presence or absence of the PVL region accounted for the differences in pyomyositis rates between lineages. It was common in pyomyositis-associated lineages including CC-121 and absent from carriage/non-pyomyositis-associated lineages including ST-834 and CC-45 ([Figure 1](#fig1){ref-type="fig"}), explaining over 99.9% of observed heritability in case-control status. It was infrequent in the non-pyomyositis-associated sub-lineage of CC-121 (2/36, 5.6%), and sporadically present in pyomyositis cases in otherwise non-pyomyositis-associated, PVL-negative strains CC-1 and CC-88. Its absence from only three cases (in lineages CC-88, CC-1 and CC-121) suggested that the PVL region approached necessity for development of pyomyositis in the current setting in Cambodian children, while its presence in 20% of controls indicated that PVL-associated pyomyositis is incompletely penetrant, that is presence of the PVL region does not always lead to disease.

PVL genes were carried on multiple genetic backgrounds in this population, and the phage backgrounds vary by clonal complex. We examined all assemblies for sequence similarity to six known bacteriophages that carry the PVL genes, ([@bib3]) as well as the 45.7 kb region in PYO2134, a hypothesised integrated prophage identified in the reference genome prepared for this study, which we have called φCC121 ([Figure 2---figure supplement 3](#fig2s3){ref-type="fig"}). The finding of PVL genes on BLAST corresponded completely with the presence of kmers mapping across the PVL locus. We find sequences with \>95% homology to four of these seven phages in the population. Regions in some assemblies showed homology for multiple phages, reflecting the similarity between jSLT, jSa2USA and jCC121 rather than the presence of multiple phages, and resolution of phages was limited by fragmented assemblies from short reads (Supplementary File 2B). Phage types were restricted within most lineages, with jSLT found in ST-3206, jSa2USA in ST-1232 and jPVL in CC-1. jCC121 was the phage most often identified in the dominant pyomyositis strain CC-121, but it was absent in all but one isolate from the low risk subclade within CC-121. Strikingly, PVL-negative isolates in CC-121 and ST-834 strains frequently retained sequence homologous to \>95% of jSLT, suggesting that some PVL-negative CC-121 isolates lost PVL secondarily by gene deletion rather than prophage excision.

Discussion {#s3}
==========

In this study, we found a strong association between pyomyositis, a highly distinctive tropical infection of skeletal muscle in children, and Panton-Valentine leukocidin, a bacterial toxin commonly carried by bacteriophages. We found that a single coding region together with the upstream sequence are all but necessary for the development of pyomyositis: its sporadic presence is associated with pyomyositis in otherwise low-frequency strains, and its absence is associated with asymptomatic carriage in a high-propensity strain. PVL appears to be carried on multiple phage backgrounds in this population, but PVL-positive lineages generally carry a single phage type, as expected given the observed strain restriction of phages in *S. aureus* ([@bib57]; [@bib51]). The locally common PVL-positive CC-121 lineage contributes most strongly to the prevalence of pyomyositis in Cambodian children.

While PVL has long been thought an important *S. aureus* virulence factor, ([@bib15]; [@bib4]; [@bib24]) its role in invasive disease has been controversial, ([@bib40]; [@bib11]) with conflicting results in case-control studies and an absence of supporting evidence on meta-analysis ([@bib46]). In previous studies, the PVL-positive USA300 lineage was associated with musculoskeletal infection (both pyomyositis and osteomyelitis), however in these studies almost all such infections were caused by the USA300 strain, so the role of PVL was almost completely confounded by both methicillin resistance and strain background ([@bib41]; [@bib4]). In our study, this confounding influence is broken down by the movement of PVL on mobile genetic elements (MGEs). Despite the emergence of CA-MRSA in carriage in Cambodia ([@bib37]), all the pyomyositis cases were MSSA ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). By applying a GWAS method to a well-powered cohort, our study resolves the controversy around pyomyositis and PVL, demonstrating strong heritability which localises to a single region, even when the full bacterial genome is considered. Bacterial GWAS can pinpoint virulence variants when MGEs act to unravel linkage disequilibrium, if effect sizes are sufficiently strong.

There is strong biological plausibility for the association demonstrated in this study. PVL is a well characterised *S. aureus* toxin, toxic to the myeloid cells that form a first line of defence against bacterial infection, ([@bib39]) and, in binding to myeloid cells by a complement receptor (C5aR), exerts immunomodulatory effects ([@bib49]). The establishment of muscle abscesses is a critical step in the pathogenesis of pyomyositis, but unlike renal, hepatic and splenic abscesses, skeletal muscle abscesses are rarely observed in experimental models of bacteraemia, unless there is preceding muscle trauma ([@bib35]). *S. aureus* strains containing PVL show increased duration of bacteraemia in a rabbit model of sepsis, ([@bib57]) and result in larger muscle abscesses ([@bib52]). PVL has been found strongly bound to necrotic muscle in an individual with myositis associated with necrotizing fasciitis ([@bib30]). These observations support the hypothesis that PVL may facilitate bacterial seeding to muscles via the bloodstream and tropism for muscular infection.

These results establish that, for children in Cambodia, staphylococcal pyomyositis is a disease whose pathogenesis depends crucially on a single toxin. This property is shared by toxin-driven, vaccine-preventable diseases such as tetanus and diphtheria. Therefore, vaccines that generate neutralising anti-toxin antibodies against PVL ([@bib26]) might protect human populations specifically against this common tropical disease. These results also raise the hypothesis that antibiotics which decrease toxin expression, and have been recommended in some PVL-associated infections, ([@bib45]) may offer specific clinical benefit in treating pyomyositis. More generally, our study provides an example of how microbial GWAS can be used to elucidate the pathogenesis of bacterial infections and identify specific virulence genes associated with human disease.

Materials and methods {#s4}
=====================

Patient sample collection {#s4-1}
-------------------------

We retrospectively identified pyomyositis cases from the Angkor Hospital for Children in Siem Reap, Cambodia, between January 2007 and November 2011. We screened all attendances in children (≤16 years) using clinical coding (ICD-10 code M60 (myositis)) and isolation of *S. aureus* from skeletal muscle abscess pus. We reviewed clinical notes to confirm a clinical diagnosis of pyomyositis was made by the medical staff, and bacterial strains cultured by routine clinical microbiology laboratory were retrieved from the local microbiology biobank. 106 clinical episodes of pyomyositis were identified, in 101 individuals, and we included the earliest episode from each individual.

We identified *S. aureus* nasal colonisation from two cohort studies undertaken at Angkor Hospital for Children. The first were selected from a collection characterising nasal colonization in the region between September and October, 2008, which has previously been described using multi-locus sequence typing ([@bib37]). The swabs had been saved at −80°C since the study, these samples were re-examined for the presence of *S. aureus* using selective agar, confirmed using Staphaurex (Remel, Lenexa, USA) and the DNAse agar test (Oxoid, Hampshire, UK). Antimicrobial susceptibility testing was performed according to the 2014 Clinical and Laboratory Standards Institute guidelines (M100-24) ([@bib9]).

We undertook a second cohort study in 2012. Inclusion criteria were children (≤16 years) attending as an outpatient at Angkor Hospital for Children with informed consent. There were no exclusion criteria. Children were swabbed between the 2-7th July 2012, using sterile cotton tipped swabs pre-moistened (with phosphate buffered saline, PBS) using three full rotations of the swab within the anterior portion of each nostril with one swab being used for both nostrils, the ends were broken into bottles containing sterile PBS and kept cool until plated in the laboratory (within the hour). The swabs were plated onto Mannitol Salt agar to select for *S. aureus*. The M100-24 CLSI ([@bib9]) standards were followed for susceptibility testing and bacteria stored in tryptone soya broth and glycerol at −80°C.

We selected controls from carriers in these two cohorts using the excel randomization function: 222 of 519 from the 2008 cohort and 195 of 261 from the 2012 cohort.

Ethical framework {#s4-2}
-----------------

Approval for this study was provided by the AHC institutional review board and the Oxford Tropical Ethics Committee (507-12).

Whole genome sequencing {#s4-3}
-----------------------

For each bacterial culture, a single colony was sub-cultured and DNA was extracted from the sub-cultured plate using a mechanical lysis step (FastPrep; MPBiomedicals, Santa Ana, CA) followed by a commercial kit (QuickGene; Autogen Inc, Holliston, MA), and sequenced at the Wellcome Centre for Human Genetics, Oxford on the Illumina (San Diego, California, USA) HiSeq 2500 platform, with paired-end reads 150 base pairs long.

A subset of samples were sequenced using long-read sequencing technology. We selected 37 isolates with incomplete assembly upstream of the PVL locus, 22 with ambiguous base calls in the assembly, and 15 where the region was assembled over two contigs. DNA was extracted using Genomic Tip 100/G (Qiagen, Manchester, UK) and DNA libraries prepared using Oxford Nanopore Technologies (ONT) SQK-LSK108 library kit (ONT, Oxford, UK) according to manufacturer instructions. These were then sequenced on ONT GridION device integrated with a FLO-MIN106 flow cell (ONT, Oxford, UK). ONT base calling was performed using Guppy v.1.6.

Variant calling {#s4-4}
---------------

For short-read sequencing, we used Velvet ([@bib59]) v1.0.18 to assemble reads into contigs de novo. Velvet Optimiser v2.1.7 was used to choose the kmer lengths on a per sequence basis. The median kmer length was 123 bp (IQR 119--123). To obtain multilocus sequence types we used BLAST ([@bib1]) to find the relevant loci, and looked up the nucleotide sequences in the online database at <http://saureus.mlst.net/.> Strains that shared 6 of 7 MLST loci were considered to be in the same Clonal Complex ([@bib19]). Antibiotic sensitivity was predicted by interrogating the assemblies for a panel of resistance determinants as previously described ([@bib22]).

We used Stampy ([@bib32]) v1.0.22 to map reads against reference genomes (USA300_FPR3757, Genbank accession number CP000255.1) ([@bib14]). Repetitive regions, defined by BLAST ([@bib1]) comparison of the reference genome against itself, were masked prior to variant calling. Bases were called at each position using previously described quality filters ([@bib12]; [@bib58]; [@bib21]).

After filtering ONT reads with filtlong v.0.2.0 (with settings filtlong \-- min_length 1000 \--keep_percent 90 \--target_bases 500000000 \--trim \--split 500), hybrid assembly of short (Illumina) and long (ONT) reads were made, using Unicycler v0.4.5 ([@bib56]) (default settings). The workflow for these assemblies is available at <https://gitlab.com/ModernisingMedicalMicrobiology/MOHAWK>)

Reconstructing the phylogenetic tree {#s4-5}
------------------------------------

We constructed a maximum likelihood phylogeny of mapped genomes for visualization using RAxML ([@bib50]) assuming a general time reversible (GTR) model. To overcome a limitation in the presence of divergent sequences whereby RAxML fixes a minimum branch length that may be longer than a single substitution event, we fine-tuned the estimates of branch lengths using ClonalFrameML ([@bib13]).

Kmer counting {#s4-6}
-------------

We used a kmer-based approach to capture non-SNP variation ([@bib47]). Using the de novo assembled genome, all unique 31 base haplotypes were counted using dsk ([@bib44]). If a kmer was found in the assembly, it was counted present for that genome, otherwise it was treated as absent. This produced a set of 10,744,013 variably present kmers, with the presence or absence of each determined per isolate. We identified a median of 2,801,000 kmers per isolate, including variably present kmers and kmers common to all genomes (IQR 2,778,000--2,837,000).

Calculating heritability {#s4-7}
------------------------

We used the Genome-wide Efficient Mixed Model Association tool (GEMMA ([@bib60])) to fit a univariate linear mixed model for association between a single phenotype (pyomyositis vs asymptomatic nasal carriage). We calculated the relatedness matrix from kmers, and used GEMMA to estimate the proportion of variance in phenotypes explained by genotypic diversity in the sample set (i.e. estimated heritability). Heritability estimates with and without a covariate (e.g. the presence of high risk kmers) are compared by testing for difference in proportions. We use the point estimate for heritability as the denominator to calculate the relative decrease proportion.

Genome wide association testing of kmers {#s4-8}
----------------------------------------

We performed association testing using an R package bacterialGWAS (<https://github.com/jessiewu/bacterialGWAS>), which implements a published method for locus testing in bacterial GWAS ([@bib17]). The association of each kmer on the phenotype was tested, controlling for the population structure and genetic background using a linear mixed model (LMM) implemented in GEMMA ([@bib20]). The parameters of the linear mixed model were estimated by maximum likelihood and likelihood ratio test was performed against the null hypothesis (that each locus has no effect) using the software GEMMA ([@bib20]). GEMMA was run using a minor allele frequency of 0 to include all SNPs. GEMMA was modified to output the ML log-likelihood under the null, and alternative and --log~10~ *p* values were calculated using R scripts in the bacterialGWAS package. Unadjusted odds ratios were reported because there was no residual heritability unexplained by the most significant kmers.

To address the possibility of differing effect sizes between the two control cohorts, we have repeated the analysis after splitting the study into two groups -- early (2008 and earlier, n = 276, cases n = 54, controls n = 222) and late (2009 and later, n = 242, cases n = 47, controls n = 195). We then examined the maximum likelihood estimates produced by the LMM for kmers mapping to the PVL coding sequence in each region. The 95% CI of the estimate from each sub study were overlapping (See [Figure 2---figure supplement 4](#fig2s4){ref-type="fig"}).

Testing for lineage effects {#s4-9}
---------------------------

We tested for associations between lineage and phenotype using an R package *bugwas* (available at <https://github.com/sgearle/bugwas>), which implements a published method for lineage testing in bacterial GWAS ([@bib17]). We tested lineages using principal components. These were computed based on biallelic SNPs using the R function prcomp. To test the null hypothesis of no background effect of each principal component, we used a Wald test, which we compared against a *χ* ([@bib7]) distribution with one degree of freedom to obtain a *p* value.

Kmer mapping {#s4-10}
------------

We used Bowtie ([@bib27]) to align all 31 bp kmers from short-read sequencing to a draft reference (the de novo assembly of a CC-121 pyomyosits strain PYO2134). Areas of homology between the draft reference and well-annotated reference strains were identified by aligning sequences with Mauve ([@bib10]). For all 31 bp kmers with significant association with case-controls status, the likely origin of the kmer was determined by nucleotide sequence BLAST ([@bib1]) of the kmers against a database of all *S. aureus* sequences in Genbank.

Joint short-read and long-read analysis {#s4-11}
---------------------------------------

31 bp kmers were counted for the 37 hybrid short-read and long-read assemblies using dsk ([@bib44]). The presence or absence of all Illumina (short-read) kmers that mapped to the two PVL toxin-coding sequences and the upstream intergenic region plus the surrounding 1 kb were reassessed. For the 37 samples with hybrid assemblies, the presence/absence of these kmers was determined from the kmers counted from the hybrid assemblies. For all other samples, presence/absence was determined from the kmers counted from the short-read only assemblies. The new presence/absence patterns were tested for association with the phenotype controlling for population structure and genetic background using GEMMA ([@bib60]), using the same relatedness matrix as the original short-read analysis.

Predicting presence of PVL genes and bacteriophages {#s4-12}
---------------------------------------------------

We used BLAST to check for the relative coverage of the PVL CDS (From reference genome USA300_FPR3757 (CP000255.1) positions 1546170--1548350), as well as the entire sequence of 6 known PVL positive phages (φ2958(NC_011344.1), φPVL (NC_002321.1), φPVL108 (NC_008689.1), φSLT (NC_002661.2), φSa2MW (NC_003923.1), φSa2USA (CP000255.1)) ([@bib3]), as well as the hypothesised prophage region from PYO2134 (1571177--1616957), which we have calledφCC121. For PVL genes, we determined relative coverage of the query sequence; over 98% coverage was used as threshold for gene presence.

Multiple testing correction {#s4-13}
---------------------------

Multiple testing was accounted for by applying a Bonferroni correction ([@bib16]); the individual locus effect of a variant (kmer or PC) was considered significant if its *P* value was smaller than *α*/*n*~p~, where we took *α* = 0.05 to be the genome-wide false-positive rate and *n*~p~ to be the number of kmers or PCs with unique phylogenetic patterns, that is, unique partitions of individuals according to allele membership. We identified 236627 unique kmer patterns and 518 PCs, giving thresholds of 2.1 × 10^−7^ and 9.7 × 10^−5^ respectively.

Data availability {#s4-14}
-----------------

Sequence data have been submitted to Short Read Archive (Bioproject ID PRJNA418899). Clinical origins of sequenced strains are listed in supplementary information ([Supplementary File 4](#supp4){ref-type="supplementary-material"}).
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Panton-Valentine leukocidin is the key determinant of *Staphylococcus aureus* pyomyositis in a bacterial GWAS\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by Wendy Garrett as the Senior Editor. The following individual involved in the review of your submission has agreed to reveal his identity: John Lees (Reviewer \#2).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

The authors use genome-wide association approaches to identify Panton-Valentine leucocidin as the primary determinant of disease causation in *S. aureus* pyomyositis.

Pyomyositis is purulent infection of skeletal muscles and associated with abscess formation. There is a strong association of the pathogen *S. aureus* with pyomyositis, 90% of cases in tropical regions, and \~75% in temperate regions. This study, by a team with strong track record in tropical medicine, and GWAS, links Panton-Valentine Leucocidin (PVL), a prophage-associated virulence determinant that is variably found in the *S. aureus* population, to pyomyositis. Their work provides strong evidence for the important role of the PVL toxin in pyomyositis in a paediatric cohort in Cambodia. Whilst there have been some controversies about the role that PVL plays in particular models of disease, there is strong clinical evidence for the association of PVL with some diseases, particularly skin and soft tissue infections (SSTIs), where the formation of boils and carbuncles are common. Abscess formation is a common link between pyomyositis and SSTIs.

The manuscript is a strong contribution to the field of association studies in bacteria. They have used a carefully collected, well-matched and well phenotyped sample collection, and properly applied cutting edge mathematical approaches. The design of the study, both in the sampling and use GWAS for analysis, is appropriate for answering the question the authors set out. Also valuable is the use of long-read sequencing to resolve the region of interest in all samples. The manuscript will settle some of the controversy about the role of PV toxin, at least in this disease context.

This paper has the potential to bridge the gap from candidate gene studies of PVL to more useful GWAS approaches, possibly leading to further meta-analysis in other populations.

Essential revisions:

1\) In the Introduction and Discussion the authors state that they are trying to expand GWAS from the identification of variants under very strong selection, such as antibiotic resistance, into more subtle phenotypes with lower effects. However, there are two issues with this: i) bacterial GWAS has already been used to identify variants underlying subtle and non-resistance phenotypes. For just a few examples, see their reference 1, which analysed host preference in Campylobacter, their reference 4, which identified variants associated with invasiveness in S. pyogenes, PMID: 28742023, which looked at determinants of carriage duration in S. pneumoniae, PMID: 27997216, PMID: 28112723, PMID: 28785103, to name a few. The point about the strong selection on AMR vs. MGEs breaking up population structure is useful to make here, but instead of setting up an implication of this being the first non-proof-of-principle GWAS, please cite these studies instead. ii) The variant they have found has an enormous odds ratio, and is clearly under very strong selection. These sections should be toned down and the relevant literature cited.

2\) It is unclear from the manuscript how valid the question the authors set out to answer actually is i.e. how controversial is the role of PVL in SSTIs? Reading the introduction and some of the cited references it does look like epidemiological studies have generally supported a role of PVL in SSTIs. Taken together with work in animal models, which seem to have been overlooked in this paper\'s introduction and references (an example of such a reference would be PMID 23684309), one might view this study as a confirmation of the role of PVL, rather than resolving an ongoing debate. The Introduction therefore needs more details and referencing to describe the controversy of the PVL association, whether this is really an ongoing debate, and why GWAS is needed to resolve this.

3\) It was not clear how the high proportion of heritability explained by the PVL hit was estimated. This is a major result of this paper and should be clear. Furthermore, given the small number of samples, is it possible to provide a confidence interval, perhaps based on bootstrapping?

4\) The use of non-USA/MRSA samples is an important strength of this study (as the authors note). Can the authors provide a more quantitative justification for this advantage? It is not necessary to perform a full meta-analysis or replication study in another population, but a summary of PVL vs SSTI presence/absence in another (more frequently studied e.g. MRSA) population would be useful to support this argument.

5\) Given the multifaceted mechanisms of *S. aureus* that modulate host-cell interactions, it is not unreasonable to suppose that there are multiple factors that contribute to pathogenic processes involved in pyomyositis. From a pathological point of view, prior to the formation of abscesses that characterize pyomyositis, there is haematogenous spread of the pathogen, and therefore survival in the blood will be an important step in the disease process. In the authors\' analysis PVL clearly demonstrates a strong association. However, the paper does not extend this to examine if there are other signals beyond PVL. Figure 2A shows that there are other associations outside the prophage reaching significance and which may provide clues to other determinants contributing to disease. These should be reported and discussed.

6\) The authors have generated a strong hypothesis for the role of PVL in disease, but this is where the study ends. There is no mechanistic support for this through experimentation, or any discussion, which relates it to the pathology of disease or the cellular mechanisms involved. We agree that it is beyond the scope of the study to perform experimental work to probe the mechanistic link, but it would be helpful if the discussion were to explore the mechanistic basis of their observations and link it to pathogenicity.

7\) The authors do not explore the relationship of the PVL carrying prophages within the *S. aureus* population in the study. This is an important aspect of the genetics of *S. aureus* of this data set that impinges on disease potential. What is the diversity of the prophages observed, where are they integrated, is there evidence of PVL mobility within and between lineages? This is an element of analysis that would add to the story, and link this back to the pathogen and our understanding of its ability to cause disease.

10.7554/eLife.42486.019

Author response

> Essential revisions:
>
> 1\) In the Introduction and Discussion the authors state that they are trying to expand GWAS from the identification of variants under very strong selection, such as antibiotic resistance, into more subtle phenotypes with lower effects. However, there are two issues with this: i) bacterial GWAS has already been used to identify variants underlying subtle and non-resistance phenotypes. For just a few examples, see their reference 1, which analysed host preference in Campylobacter, their reference 4, which identified variants associated with invasiveness in S. pyogenes, PMID: 28742023, which looked at determinants of carriage duration in S. pneumoniae, PMID: 27997216, PMID: 28112723, PMID: 28785103, to name a few. The point about the strong selection on AMR vs. MGEs breaking up population structure is useful to make here, but instead of setting up an implication of this being the first non-proof-of-principle GWAS, please cite these studies instead. ii) The variant they have found has an enormous odds ratio, and is clearly under very strong selection. These sections should be toned down and the relevant literature cited.

We would like to thank the reviewers for these important points. We have modified our Introduction to include recent results, and note the phenotypes where GWAS has demonstrated an association (host specificity, invasive disease with *Streptococcus pyogenes* and *Staphylococcus epidermidis*, pneumococcal carriage, mortality following bacteraemia with CC-30 *Staphylococcus aureus*, endemic melioidosis). We have noted in discussion that the strong effect size contributes the success of this study. We have moderated the language in discussion about the importance of MGEs by noting that a large effect size was present in this study.

> 2\) It is unclear from the manuscript how valid the question the authors set out to answer actually is i.e. how controversial is the role of PVL in SSTIs? Reading the introduction and some of the cited references it does look like epidemiological studies have generally supported a role of PVL in SSTIs. Taken together with work in animal models, which seem to have been overlooked in this paper\'s introduction and references (an example of such a reference would be PMID 23684309), one might view this study as a confirmation of the role of PVL, rather than resolving an ongoing debate. The Introduction therefore needs more details and referencing to describe the controversy of the PVL association, whether this is really an ongoing debate, and why GWAS is needed to resolve this.

It is important to clarify that our study is of pyomyositis, not skin and soft tissue infections. As the reviewers observe, PVL is widely accepted as a virulence factor for superficial skin and soft tissue infections such as abscesses, boils and furunculosis (see Shallcross et al., 2013 and Saeed et al., 2017). However pyomyositis remains a distinct entity of invasive disease observed in tropical areas, with the formation of purulent infection within skeletal muscle, while the overlying skin remains intact. Unlike infections of the skin and superficial soft tissues, the skin and subcutaneous tissues are not usually involved in pyomyositis, by contrast to intense inflammation in the infected muscles. Pyomyositis is thought to arise from haematogenous seeding of bacteria from blood to muscle (See Verma et al., 2016). Reviews of the role of PVL in disease -- including the two cited here -- generally separate it from skin and soft tissue infections, categorising it among musculoskeletal infections.

We have researched the question extensively and believe that the studies supporting and refuting the association of PVL are yet to provide an unequivocal answer to the question. In conducting this study, we started without a hypothesis that we would find specific causative genes associated with pyomyositis; our aim was to investigate whether any bacterial genetic factors contribute to the characteristic disease entity of pyomyositis. Given the striking results localised to a single gene, and because prominent results reporting association between PVL with other conditions (e.g. necrotising pneumonia) have been controversial, we chose to contextualise the results early with a discussion of PVL as a virulence factor, including what is known about its possible contribution to pyomyositis. However, the discussion of PVL in the introduction should not indicate that this was a study designed to investigate the role of PVL in pyomyositis. We have clarified this further in the Introduction.

We would strongly contend that no strong evidence establishes an association between PVL and pyomyositis prior to this study. Indeed, in the article on mechanisms of action of PVL suggested here (PMID 23684309), the authors note "the role of PVL is still under debate". In the meta-analysis conducted by Shallcross et al., the authors find that in contrast to the strong association with skin and soft tissue infections, PVL strains are comparatively rare in musculoskeletal infections (OR 0.44, CI 0.19-0.99). In the ISAC position statement on PVL, they find the association between PVL and SSTI is highest for furuncuolisis. This review presents limited statements on musculoskeletal infection. They do note "PVL-SA are also associated with severe musculoskeletal infections, particularly in children", but the only evidence they present (Sheikh et al., 2015, British Journal of hospital medicine) is a review specifically of osteomyelitis. It is notable that this review cites as evidence the meta-analysis by Shallcross et al., which found existing evidence for an association between musculoskeletal infection and PVL was weak. The review by Sheikh et al. further supports the claims of association with studies that report non-significant results on tests of association: "Panton-Valentine leukocidin-producing *S. aureus* osteomyelitis can be multifocal with multiple bones involved. Patients are also more likely to present with large sub-periosteal abscesses (risk ratio 3.90, *P*=0.25) \[...\] and associated myositis and/or pyomyositis (risk ratio 3.22, *P*=0.18)\[...\]."

To address this concern, and to avoid any unintended confusion between pyomyositis and superficial SSTI, we have therefore included further detail throughout our introduction to reiterate the aims of this study (to undertake an unbiased survey of the whole genome, rather than hypothesis driven investigation), and its focus on the invasive, distinctive pathological entity of pyomyositis rather than superficial skin and soft tissue infection. We have also expanded the literature review to clearly state why we believe our results illuminate an ongoing debate rather than confirm a settled answer.

> 3\) It was not clear how the high proportion of heritability explained by the PVL hit was estimated. This is a major result of this paper and should be clear. Furthermore, given the small number of samples, is it possible to provide a confidence interval, perhaps based on bootstrapping?

We determined this figure by including the presence of the most significant kmer, which tags PVL, as a covariate in the linear mixed model. When this is included, the estimate of heritability output by the model (in GEMMA), which represents the estimated proportion of heritability not explained by other factors, drops from 63.8% to 0.0%. Thus, the proportion of difference explained ((p1-p2)/p1) is over 99.99% (95% CI 93.5-100%). We have included this more detailed description of the heritability results (Results paragraph seven), including the confidence interval for proportion accounted for, and added to the relevant Materials and methods section (subsection "Genome wide association testing of Kmers.").

> 4\) The use of non-USA/MRSA samples is an important strength of this study (as the authors note). Can the authors provide a more quantitative justification for this advantage? It is not necessary to perform a full meta-analysis or replication study in another population, but a summary of PVL vs SSTI presence/absence in another (more frequently studied e.g. MRSA) population would be useful to support this argument.

With apologies, we do not understand what this question seeks to address. We do not believe that evidence about prevalence of PVL in skin and soft tissue infections can be directly applied to help our understanding of primary, invasive muscle infection. Regarding pyomyositis, limited studies exist. Our paper references a meta-analysis, which summarises the prevalence of PVL in existing high-quality studies of musculoskeletal infections. Only two of these studies were of pyomyositis (the rest being bone and joint infections), and neither had carriage control populations (one had skin and soft tissue infections as a comparator group, and the other was a case series without control group). The findings and limitations of studies of CA-MRSA and pyomyositis are detailed in the Discussion.

> 5\) Given the multifaceted mechanisms of S. aureus that modulate host-cell interactions, it is not unreasonable to suppose that there are multiple factors that contribute to pathogenic processes involved in pyomyositis. From a pathological point of view, prior to the formation of abscesses that characterize pyomyositis, there is haematogenous spread of the pathogen, and therefore survival in the blood will be an important step in the disease process. In the authors\' analysis PVL clearly demonstrates a strong association. However, the paper does not extend this to examine if there are other signals beyond PVL. Figure 2A shows that there are other associations outside the prophage reaching significance and which may provide clues to other determinants contributing to disease. These should be reported and discussed.

This is an important point, and the incomplete penetrance of PVL suggests other factors (host, bacterial or environmental) in the pathogenic process. However, we have little evidence for any remaining bacterial genetic heritability (see point 3 above for a formal demonstration of this). Following the reviewers' suggestion, we have included a discussion of the analysis of significant kmers outside of the prophage region (Results paragraph six, Supplementary file 2). These findings are cautiously interpreted, given the very low remaining heritability once PVL is accounted for.

> 6\) The authors have generated a strong hypothesis for the role of PVL in disease, but this is where the study ends. There is no mechanistic support for this through experimentation, or any discussion, which relates it to the pathology of disease or the cellular mechanisms involved. We agree that it is beyond the scope of the study to perform experimental work to probe the mechanistic link, but it would be helpful if the discussion were to explore the mechanistic basis of their observations and link it to pathogenicity.

We agree, this is a helpful addition to the observations of our study. We have included discussion on the extensive experimental work that has previously reported plausible mechanism for the action of PVL in muscle infections (Discussion section).

> 7\) The authors do not explore the relationship of the PVL carrying prophages within the S. aureus population in the study. This is an important aspect of the genetics of S. aureus of this data set that impinges on disease potential. What is the diversity of the prophages observed, where are they integrated, is there evidence of PVL mobility within and between lineages? This is an element of analysis that would add to the story, and link this back to the pathogen and our understanding of its ability to cause disease.

We agree this is a helpful development of the study results. We have added a section in results discussing the diversity of phages within and between lineages (Discussion paragraph nine, (see also Figure 2---figure supplement 4, Supplementary file 3). There are challenges to the study of phages with short read sequencing data; in almost all isolates the likely phage sequences are fragmented, so an analysis of the integration of prophages is not currently possible. However we think the question of phage integration throughout the population, while an important question, is incidental to the current study's main result.
